symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
HSTO,0.7801,1.030482,238473,3332400,0,0.36-1.64,-0.0199,Histogen Inc.,USD,0001383701,US43358Y1038,43358Y103,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.histogen.com,"Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.",Ms. Susan A. Knudson,Healthcare,US,7,858 526 3100,10655 Sorrento Valley Road,San Diego,CA,92121,4.90346,5.92346,https://financialmodelingprep.com/image-stock/HSTO.png,2013-07-25,False,False,True,False,False
